GEN Exclusives

More »

GEN News Highlights

More »
Feb 7, 2007

Diosynth Extends Commercial Supply Ageement with PDL BioPharma

  • Diosynth Biotechnology signed an extension of its exclusive agreement with PDL BioPharma for the commercial manufacture of Retavase® (reteplase), a fibrinolytic agent that has been marketed in North America since October 1996.

    Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »